[Clinical studies on chloroquine-resistant Plasmodium falciparum]. 1968

J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D008297 Male Males
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial

Related Publications

J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
January 1964, Bulletin of the World Health Organization,
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
January 1988, Therapia Hungarica (English edition),
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
May 1983, Lancet (London, England),
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
December 2021, The Lancet. Infectious diseases,
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
January 1979, Lancet (London, England),
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
August 1983, MMWR. Morbidity and mortality weekly report,
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
January 1976, Transactions of the Royal Society of Tropical Medicine and Hygiene,
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
May 1985, Lancet (London, England),
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
January 1964, Bulletin of the World Health Organization,
J V McNamara, and K H Rieckmann, and T A Stockert, and H Frischer, and P E Carson, and R D Powell
May 2009, Emerging infectious diseases,
Copied contents to your clipboard!